News | Cath Lab | January 30, 2019

Scientists Discover New Heart Attack Repair Pathway

Study provides insight on how dead heart cells are consumed and reprogrammed by macrophages

Scientists Discover New Heart Attack Repair Pathway

A macrophage immune cell, with a dead cell (pink) that has been eaten, and a mitochondrion (green) between the dead cell and the nucleus. The study’s findings indicate that what the macrophage eats is taken up by the mitochondrion, which in turn communicates with the nucleus to activate the macrophage to promote tissue repair. Image courtesy of Northwestern Medicine.


January 30, 2019 — Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack. The study, published in Cell Metabolism, demonstrates for the first time that the metabolism of dead heart cells by macrophages reprograms the immune cells to launch an anti-inflammatory response and stimulate tissue repair.

“Targeting this pathway may have therapeutic benefit for a broad range of acute and chronic disorders — not only heart attacks — by enhancing the active resolution of inflammation,” said principal investigator Edward Thorp, Ph.D., associate professor of pathology and a member of the Feinberg Cardiovascular and Renal Research Institute (FCVRI).

Shuang Zhang, Ph.D., who recently graduated from Feinberg’s Driskill Graduate Program in Life Sciences (DGP), was the first author.

The Thorp Laboratory studies how immune cells regulate wound healing, in particular after myocardial infarction, or heart attack. After a patient has experienced a heart attack, immune cells are essential for removing dead or dying heart cells. If the cells are not cleared efficiently, they can lead to prolonged inflammation and cause further damage to the heart.

There are currently few effective treatments to enhance the healing process after a heart attack, and many patients go on to develop heart failure as a result of the damage.

The Thorp Laboratory has published extensively on efferocytosis — the process by which immune cells called macrophages engulf and ingest dying cells — and its critical role in turning on inflammation resolution after heart attack. But the intracellular mechanisms of the process remained unclear.

In the new research, the scientists discovered that when macrophages swallow dead heart cells during efferocytosis, the macrophages fill with metabolites that reprogram the cell to initiate an anti-inflammatory response and promote repair of the heart.

“Our findings elucidate a novel process by which dead tissue metabolites are recycled to fuel wound healing,” Thorp explained. “It extends the meaning of ‘you are what you eat’ to the cellular level.”

In an experimental model, the scientists further demonstrated that when mitochondria — an organelle which regulates metabolism — are defective, healing after cardiac injury is impaired.

The findings suggest a novel role for immune cell metabolism beyond the production of energy.

“The idea that mitochondria, or overall metabolism, can act as a dictator of the cell and control macrophage function — that’s very novel,” Zhang said.

The Thorp Laboratory is continuing to investigate metabolic control of human immune cell function in further studies of cardiac injury and organ transplantation. Zhang is beginning a post-doctoral fellowship at Harvard Medical School, where she will continue her study of immune cells.

For more information: www.cell.com/cell-metabolism

Reference

1. Zhang S., Weinberg S., DeBerge M., et al. Efferocytosis Fuels Requirements of Fatty Acid Oxidation and the Electron Transport Chain to Polarize Macrophages for Tissue Repair. Cell Metabolism, Dec. 27, 2018. https://doi.org/10.1016/j.cmet.2018.12.004


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now